When used as an anterolateral non-pedicle screw system in the thoracic and lumbar spine, the NuVasive Long Lateral Spinal System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the spine: (1) degenerative disc disease (as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), (2) spinal stenosis, (3) spondylolisthesis, (4) spinal deformities, (5) fracture, (6) pseudoarthosis, (7) tumor resection, and/or (8) failed previous fusion.

Device Description

The NuVasive Long Lateral Spinal System consists of a variety of screws, rods, staples, and caps. Implant components can be rigidly locked into a variety of different configurations to suit the individual pathology and anatomical conditions of the patient.

AI/ML Overview

The NuVasive Long Lateral Spinal System is a medical device designed for spinal stabilization. The provided documents focus on its substantial equivalence to predicate devices rather than independent performance metrics where "acceptance criteria" and "device performance" would typically refer to clinical accuracy or diagnostic efficacy.

Here's an interpretation of the request based on the provided 510(k) summary:

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria (from 510(k))	Reported Device Performance (from 510(k))
Substantial equivalence to predicate devices (K091502, K011556, K965145, K993030) in areas including: design, intended use, material composition, function, and range of sizes.	The device was shown to be substantially equivalent and have the same technological characteristics to its predicate devices.
Meet or exceed performance of predicate device for mechanical stability.	Results of static and dynamic compression testing (per ASTM F1717) and static torsion testing (per ASTM F1717) show that the subject Long Lateral Spinal System meets or exceeds the performance of the predicate device.
Safe and effective for intended use.	Based on performance testing and comparison to predicate devices, the device was found safe and effective for its intended use.

2. Sample size used for the test set and the data provenance

Sample size for the test set: Not applicable in this context. The "test set" here refers to the mechanical testing performed on the device components, not a clinical data set. The documents do not specify the number of units or replicates tested for the mechanical evaluations.
Data provenance: The data comes from "nonclinical testing" performed by NuVasive, Inc. The exact location or origin of the materials tested is not specified (e.g., country of origin). The testing is inherently prospective for the purpose of demonstrating mechanical equivalence.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Not applicable. "Ground truth" in this 510(k) context refers to the established standards for mechanical performance (e.g., ASTM F1717) and the performance of the predicate devices. Expert consensus on clinical ground truth is not relevant for this type of submission. The evaluation was conducted by NuVasive's R&D and regulatory teams.

4. Adjudication method for the test set

Not applicable. This device utilizes non-clinical mechanical testing, not a clinical study requiring adjudication of expert interpretations.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, or an effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This is a spinal implant system, not a diagnostic AI device. Therefore, MRMC studies or AI assistance for human readers are not relevant.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

Not applicable. This is a physical medical device, not an algorithm.

7. The type of ground truth used

The "ground truth" for this 510(k) submission is primarily based on:

Benchmarking against predicate devices: The performance and characteristics of the legally marketed predicate devices (K091502, K011556, K965145, K993030) serve as the standard for substantial equivalence.
Industry standards: Adherence to established ASTM International standards (ASTM F1717 for static and dynamic mechanical testing) dictates the methodology and acceptable parameters for evaluating device performance.

8. The sample size for the training set

Not applicable. There is no "training set" in the context of this 510(k) submission for a physical medical device.

9. How the ground truth for the training set was established

Not applicable, as there is no training set.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for Nuvasive. The logo consists of a stylized, abstract shape on the left, followed by the word "NUVASIVE" in capital letters. Below the word "NUVASIVE" is the tagline "Speed of Innovation" in a smaller font.

510(k) Premarket Notification Long Lateral Spinal System

510(k) Summary

JUN 2 0 2011

In accordance with Title 21 of the Code of Federal Regulations, Part 807, and in particular 21 CFR §807.92, the following summary of information is provided:

Submitted by: A.

Elias Ketchum Regulatory Affairs Associate NuVasive, Incorporated 7475 Lusk Blvd. San Diego, California 92121 Telephone: (858) 320-4588 Fax: (858) 320-4688

Date Prepared: May 16, 2011

B. Device Name

Trade or Proprietary Name:	NuVasive® Long Lateral Spinal System
Common or Usual Name:	Anterior/ Anterolateral, Noncervical System
Classification Name:	Spinal Intervertebral Body Fixation orthosis
Device Class:	Class II
Classification:	§888.3060
Product Code:	KWQ

C. Predicate Devices

The subject Long Lateral Spinal System is substantially equivalent to the following devices:

· K091502 NuVasive, Inc. SpheRx Spinal System
· K011556 -- Aesculap MACS TL HMA Anterior Spinal Stabilization System
· K965145 DePuy, Inc. Moss Miami Ti
· K993030 DePuy, Inc. ISOLA

D. Device Description

E. Intended Use

When used as an anterolateral non-pedicle screw system in the thoracic and lumbar spine, the NuVasive Long Lateral System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the spine: (1) degenerative disc disease (as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), (2) spinal stenosis, (3) spondylolisthesis, (4) spinal deformities, (5) fracture, (6) pseudoarthosis, (7) tumor resection, and/or (8) failed previous fusion.

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the logo for Nuvasive. The logo consists of a stylized eye-like graphic on the left, followed by the word "NUVASIVE" in bold, sans-serif font. Below the word "NUVASIVE" is the tagline "...Speed of Innovation" in a smaller, italicized font.

Technological Characteristics F.

As was established in this submission, the subject Long Lateral Spinal System is substantially equivalent to other predicate devices cleared by the FDA for commercial distribution in the United States. The subject device was shown to be substantially equivalent and have the same technological characteristics to its predicate devices through comparison in areas including design, intended use, material composition, function, and range of sizes.

G. Performance Data

Nonclinical testing was performed to demonstrate that the subject Long Lateral Spinal System is substantially equivalent to other predicate devices. The following testing was performed:

. Static and dynamic compression testing per ASTM F1717
Static torsion testing per ASTM F1717 .

The results of these studies show that the subject Long Lateral Spinal System meets or exceeds the performance of the predicate device, and the device was therefore found to be substantially equivalent.

H. Conclusions

Based on the indications for use, technological characteristics, performance testing, and comparison to predicate devices, the subject Long Lateral Spinal System has been shown to be substantially equivalent to legally marketed predicate devices, and safe and effective for its intended use.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with outstretched wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the bird-like figure.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

NuVasive, Incorporated % Mr. Elias Ketchum Regulatory Affairs Associate 7475 Lusk Boulevard San Diego, California 92121

JUN 2 0 2011

Re: K111410

Trade/Device Name: NuVasive® Long Lateral Spinal System Regulation Number: 21 CFR 888.3060 Regulation Name: Spinal intervertebral body fixation orthosis -Regulatory Class: Class II · Product Code: KWO Dated: May 17, 2011 Received: May 27, 2011

Dear Mr. Ketchum:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

{3}------------------------------------------------

Page 2 – Mr. Elias Ketchum

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely vours.

Ernst Ruth

for

Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Indications for Use

510(k) Number (if known):__K111410

Device Name:

Indications For Use:

Over-The-Counter Use AND/OR Prescription Use × (21 CFR 807 Subpart C) (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF

NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number_________________________________________________________________________________________________________________________________________________________________

Regulation Number and Section

§ 888.3060 Spinal intervertebral body fixation orthosis.

(a)
Identification. A spinal intervertebral body fixation orthosis is a device intended to be implanted made of titanium. It consists of various vertebral plates that are punched into each of a series of vertebral bodies. An eye-type screw is inserted in a hole in the center of each of the plates. A braided cable is threaded through each eye-type screw. The cable is tightened with a tension device and it is fastened or crimped at each eye-type screw. The device is used to apply force to a series of vertebrae to correct “sway back,” scoliosis (lateral curvature of the spine), or other conditions.(b)
Classification. Class II.